Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Systemic Lupus meeting the ACR (American College of Rheumatology) criteria, progressive either SLEDAI activity score ≥ 4, despite a corticosteroid therapy ≥ 10 mg / d associated with hydroxychloroquine (in the absence of contraindication or intolerance) and / or an immunosuppressive treatment at a stable dose,~* Insured,~* Availability for hospitalization required by the protocol (conventional and daily hospitalizations).~Exclusion Criteria:~* Inability to give their signed informed consent form,~* Performans status \> 2~* QTcorrected space before treatment \> 0.45 seconds~* Hemoglobin less than 11g/dL~* Neutrophils rate below 1 200 / mm3~* Platelets rate below 100 Giga / mm3~* Previous history of arrhythmia or heart rhythm disorder or other rhythm trouble by referring cardiologist~* Heart disorder (progressive pericarditis, valvular disease, ...) according to cardiologist~* Family previous history of arrhythmias~* Taking drugs that potentially prolong the QT~* Hypersensitivity to the active substance of Trisenox® or any of the excipients~* Serum potassium ≤ 4 milliequivalent / L~* Magnesemia ≤ 1,8 mg / dl~* Increase corticosteroids beyond 20 mg / day within 15 days before inclusion~* Immunosuppressive treatments, thalidomide introduced within the last 3 months~* Biotherapy (rituximab, belimumab, ...) introduced within 6 months prior to inclusion~* Pregnancy or lactation~* For women of childbearing age, men and their partner : unless effective contraception for the duration of participation in the study that is 7 months~* Creatinine clearance \<50 ml / min,~* Hepatocellular insufficiency (TP \<50%), and / or AST (aspartate aminotransferase) / ALT (alanine aminotransferase) / ALP (alkaline phosphatase) \> 2N~* HBsAg positive, DNA detectable HbS~* Infection with HIV, HBV (hepatitis B virus) or HCV (hepatitis C virus)~* Renal or progressive central neurological impairment with possible alternative therapeutic (to be discussed with the principal investigator and scientific board meeting)~* Peripheral neuropathy~* Unweaned alcoholism~* Minor~* Patients older than 65 years~* Patient having been professionally exposed to arsenic (cleaning electronic circuits for example)~* Guardianship patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arsenic trioxide (Type: EXPERIMENTAL): Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day).

Based on this trial design, predict the completion outcome and termination type (if applicable).